<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:media="http://search.yahoo.com/mrss/" > <channel> <title>Pharmafile</title> <atom:link href="https://pharmafile.com/feed/" rel="self" type="application/rss+xml" /> <link>https://pharmafile.com</link> <description>Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, insights, analysis and events.</description> <lastBuildDate>Fri, 14 Feb 2025 11:54:21 +0000</lastBuildDate> <language>en-GB</language> <sy:updatePeriod> hourly </sy:updatePeriod> <sy:updateFrequency> 1 </sy:updateFrequency> <site xmlns="com-wordpress:feed-additions:1">218578772</site> <item> <title>PulseSight Therapeutics closes Series A financing for dry AMD phase 1 clinical study</title> <link>https://pharmafile.com/news/pulsesight-therapeutics-closes-series-a-financing-for-dry-amd-phase-1-clinical-study/</link> <dc:creator><![CDATA[Natalia Elliot]]></dc:creator> <pubDate>Fri, 14 Feb 2025 11:54:15 +0000</pubDate> <category><![CDATA[age-related macular degeneration]]></category> <category><![CDATA[clinical trials]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&#038;p=40291</guid> <description><![CDATA[<p>Ophthalmology biotech PulseSight Therapeutics has confirmed the closure of its Series A funding round, the proceeds of which will be used to fund a phase 1 study into its dry age-related macular degeneration (AMD) therapy, PST-611. The funding round was supported by existing investor Pureos BioVentures. PST-611 is a non-viral vectorised therapy indicated for the [&#8230;]</p> <p>The post <a rel="nofollow" href="https://pharmafile.com/news/pulsesight-therapeutics-closes-series-a-financing-for-dry-amd-phase-1-clinical-study/">PulseSight Therapeutics closes Series A financing for dry AMD phase 1 clinical study</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40291</post-id> </item> <item> <title>Cardinal Health’s Kangaroo OMNI™ Enteral Feeding Pump to launch in new international markets in 2025</title> <link>https://pharmafile.com/news/cardinal-healths-kangaroo-omni-enteral-feeding-pump-to-launch-in-new-international-markets-in-2025/</link> <dc:creator><![CDATA[Natalia Elliot]]></dc:creator> <pubDate>Thu, 06 Feb 2025 17:47:26 +0000</pubDate> <category><![CDATA[enteral]]></category> <category><![CDATA[feeding pump]]></category> <category><![CDATA[Kangaroo]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&#038;p=40289</guid> <description><![CDATA[<p>The next generation Kangaroo OMNI™ enteral feeding pump delivers nutrition and hydration from hospital to home. DUBLIN, Ireland, Feb.4, 2025 &#8211; Cardinal Health’s innovative new Kangaroo OMNI™ Enteral Feeding Pump will be launched in Europe, Australia and New Zealand by the first half of 2025, followed by Asia later in the year. It previously launched [&#8230;]</p> <p>The post <a rel="nofollow" href="https://pharmafile.com/news/cardinal-healths-kangaroo-omni-enteral-feeding-pump-to-launch-in-new-international-markets-in-2025/">Cardinal Health’s Kangaroo OMNI™ Enteral Feeding Pump to launch in new international markets in 2025</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40289</post-id> </item> <item> <title>European Commission launches new Biotech and Biomanufacturing Hub</title> <link>https://pharmafile.com/news/european-commission-launches-new-biotech-and-biomanufacturing-hub/</link> <dc:creator><![CDATA[Natalia Elliot]]></dc:creator> <pubDate>Mon, 03 Feb 2025 12:50:28 +0000</pubDate> <category><![CDATA[Biomanufacturing]]></category> <category><![CDATA[European Commission]]></category> <category><![CDATA[european union]]></category> <category><![CDATA[Hub]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&#038;p=40285</guid> <description><![CDATA[<p>The European Commission has announced the opening of a new Biotech and Biomanufacturing Hub, supporting start-ups and small- to medium-sized enterprises (SMEs) in bringing new innovations to the EU market. The Hub, hosted on the EU Commission’s Your Europe portal, is in all EU languages and explains such things as: the sources of EU funding [&#8230;]</p> <p>The post <a rel="nofollow" href="https://pharmafile.com/news/european-commission-launches-new-biotech-and-biomanufacturing-hub/">European Commission launches new Biotech and Biomanufacturing Hub</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40285</post-id> </item> <item> <title>FlyPharma 2025 Amsterdam officially announced as contracts are signed with host sponsors</title> <link>https://pharmafile.com/news/flypharma-2025-amsterdam-officially-announced-as-contracts-are-signed-with-host-sponsors/</link> <dc:creator><![CDATA[Natalia Elliot]]></dc:creator> <pubDate>Mon, 03 Feb 2025 10:00:00 +0000</pubDate> <category><![CDATA[Air France KLM Martinair Cargo .]]></category> <category><![CDATA[Amsterdam Airport Schiphol]]></category> <category><![CDATA[DHL Global Forwarding]]></category> <category><![CDATA[FlyPharma Conferences]]></category> <category><![CDATA[logistics]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&#038;p=40278</guid> <description><![CDATA[<p>FlyPharma, the leading platform for the pharmaceutical logistics and supply chain industry, is thrilled to announce its ninth European conference, which will take place in Amsterdam from October 8-9, 2025. The FlyPharma Amsterdam 2025 conference will convene industry experts to explore the unique challenges and opportunities facing the region and beyond. In a first for [&#8230;]</p> <p>The post <a rel="nofollow" href="https://pharmafile.com/news/flypharma-2025-amsterdam-officially-announced-as-contracts-are-signed-with-host-sponsors/">FlyPharma 2025 Amsterdam officially announced as contracts are signed with host sponsors</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40278</post-id> </item> <item> <title>Prenatal care could be revolutionised suggests studies from BrightHeart</title> <link>https://pharmafile.com/news/prenatal-care-could-be-revolutionised-suggests-studies-from-brightheart/</link> <dc:creator><![CDATA[Natalia Elliot]]></dc:creator> <pubDate>Fri, 31 Jan 2025 14:15:00 +0000</pubDate> <category><![CDATA[AI]]></category> <category><![CDATA[BrightHeart]]></category> <category><![CDATA[FDA]]></category> <category><![CDATA[prenatal]]></category> <category><![CDATA[studies]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&#038;p=40273</guid> <description><![CDATA[<p>Private medical device and artificial intelligence (AI)-led company, BrightHeart, has revealed two studies which show an improvement to pre-natal care through the use of AI technology that received clearance from the US Food and Drug Administration in November 2024. At the Society for Maternal-Fetal Medicines 2025 Meeting in Colorado, US, two groundbreaking studies were presented [&#8230;]</p> <p>The post <a rel="nofollow" href="https://pharmafile.com/news/prenatal-care-could-be-revolutionised-suggests-studies-from-brightheart/">Prenatal care could be revolutionised suggests studies from BrightHeart</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40273</post-id> </item> <item> <title>CANDOR Bioscience acquired by Medix Biochemica</title> <link>https://pharmafile.com/news/candor-bioscience-acquired-by-medix-biochemica/</link> <dc:creator><![CDATA[Natalia Elliot]]></dc:creator> <pubDate>Fri, 31 Jan 2025 12:06:46 +0000</pubDate> <category><![CDATA[acquisition]]></category> <category><![CDATA[CANDOR biosciences]]></category> <category><![CDATA[in vitro diagnostics]]></category> <category><![CDATA[Medix biochemica]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&#038;p=40271</guid> <description><![CDATA[<p>CANDOR Biosciences, a supplier in immunoassay solutions, has been acquired by Medix Biochemica, a supplier of raw materials for in vitro diagnostic (IVD). This will support the vision from Medix Biochemica to become the first-in-choice partner for raw materials in the IVD industry. Medix Biochemica claim that the acquisition will strengthen its range of materials, [&#8230;]</p> <p>The post <a rel="nofollow" href="https://pharmafile.com/news/candor-bioscience-acquired-by-medix-biochemica/">CANDOR Bioscience acquired by Medix Biochemica</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40271</post-id> </item> <item> <title>MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients</title> <link>https://pharmafile.com/news/mhra-approve-new-treatment-combo-for-transplant-ineligible-multiple-myeloma-patients/</link> <dc:creator><![CDATA[Natalia Elliot]]></dc:creator> <pubDate>Thu, 30 Jan 2025 12:04:19 +0000</pubDate> <category><![CDATA[approvals]]></category> <category><![CDATA[MHRA]]></category> <category><![CDATA[multiple myeloma]]></category> <category><![CDATA[rare diseases]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&#038;p=40266</guid> <description><![CDATA[<p>The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in combination to treat multiple myeloma in patients who are ineligible for a transplant from Sanofi. The decision comes just days after approval from the European Commission. Influenced by the results of the IMROZ study, isatuximab is now licensed in the [&#8230;]</p> <p>The post <a rel="nofollow" href="https://pharmafile.com/news/mhra-approve-new-treatment-combo-for-transplant-ineligible-multiple-myeloma-patients/">MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40266</post-id> </item> <item> <title>Bayer UK Launches New CanesMeno® Educational Hub and Product Range to Transform Menopause Support</title> <link>https://pharmafile.com/news/bayer-uk-launches-new-canesmeno-educational-hub-and-product-range-to-transform-menopause-support/</link> <dc:creator><![CDATA[Natalia Elliot]]></dc:creator> <pubDate>Thu, 30 Jan 2025 09:53:23 +0000</pubDate> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&#038;p=40265</guid> <description><![CDATA[<p>29 January 2025 – Reading, UK – Bayer Consumer Health is entering the menopause category for the first time in the UK with the introduction of the new brand, CanesMeno® &#8211; an expertly crafted digital education resource and scientifically-backed product range &#8211; to help the estimated 13 million women in the UK who are currently [&#8230;]</p> <p>The post <a rel="nofollow" href="https://pharmafile.com/news/bayer-uk-launches-new-canesmeno-educational-hub-and-product-range-to-transform-menopause-support/">Bayer UK Launches New CanesMeno® Educational Hub and Product Range to Transform Menopause Support</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40265</post-id> </item> <item> <title>NICE issues positive final guidance for treatment of Duchenne Muscular Dystrophy from Santhera</title> <link>https://pharmafile.com/news/nice-issues-positive-final-guidance-for-treatment-of-duchenne-muscular-dystrophy-from-santhera/</link> <dc:creator><![CDATA[Natalia Elliot]]></dc:creator> <pubDate>Wed, 29 Jan 2025 15:30:00 +0000</pubDate> <category><![CDATA[Duchenne Muscular Dystrophy]]></category> <category><![CDATA[EC]]></category> <category><![CDATA[EMA]]></category> <category><![CDATA[FDA]]></category> <category><![CDATA[positive]]></category> <category><![CDATA[Santhera Pharmaceuticals]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&#038;p=40262</guid> <description><![CDATA[<p>Santhera Pharmaceuticals has received positive final guidance from the National Institute for Care and Excellence (NICE) for AGAMREE (vamorolone) to be used as treatment of Duchenne Muscular Dystrophy (DMD) in patients who are aged 4 or older in the UK. The guidance follows the approval of vamorolone from the Medicines and products Regulatory Agency (MHRA) [&#8230;]</p> <p>The post <a rel="nofollow" href="https://pharmafile.com/news/nice-issues-positive-final-guidance-for-treatment-of-duchenne-muscular-dystrophy-from-santhera/">NICE issues positive final guidance for treatment of Duchenne Muscular Dystrophy from Santhera</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40262</post-id> </item> <item> <title>Positive topline results announced in phase 2 Alcohol Use Disorder study</title> <link>https://pharmafile.com/news/positive-topline-results-announced-in-phase-2-alcohol-use-disorder-study/</link> <dc:creator><![CDATA[Natalia Elliot]]></dc:creator> <pubDate>Wed, 29 Jan 2025 13:07:05 +0000</pubDate> <category><![CDATA[alcohol use disorder]]></category> <category><![CDATA[Beckley Psytech Ltd]]></category> <category><![CDATA[clinical trials]]></category> <category><![CDATA[King's College University]]></category> <category><![CDATA[positive results]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&#038;p=40259</guid> <description><![CDATA[<p>Beckley Psytech Ltd, a clinical-stage biopharmaceutical company that specialises in the production of accessible medicines for mental health conditions, has announced positive results for the phase 2a study into BPL-003 in patients with moderate-to-severe Alcohol Use Disorder (AUD). The study, labelled NCT05674929, was conducted at King’s College London and Clerkenwell Health, both UK. The aim [&#8230;]</p> <p>The post <a rel="nofollow" href="https://pharmafile.com/news/positive-topline-results-announced-in-phase-2-alcohol-use-disorder-study/">Positive topline results announced in phase 2 Alcohol Use Disorder study</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40259</post-id> </item> </channel> </rss>